Tag Archives: chief-executive

Technology News | Reuters.com

Posted: March 27, 2016 at 12:44 am

Verizon Communications Inc said an attacker had exploited a security vulnerability on its enterprise client portal to steal contact information of a number of customers.

26 Mar 2016

NEW YORK Apple Inc said the U.S. Justice Department’s new attempts to unlock an iPhone used by one of the San Bernardino shooters without the tech giant’s help could eliminate the government’s need for its assistance in a similar dispute in New York.

BOAO, China Ride hailing app company Uber Technologies Inc [UBER.UL] is generating more than $1 billion in profit a year in its top 30 cities globally, and partly using that money to bankroll its expansion in China, Chief Executive Travis Kalanick said in an interview.

25 Mar 2016

SHANGHAI China’s commerce ministry said on Friday it hoped telecom equipment maker ZTE Corp could be removed as soon as possible from a U.S. list of companies slapped with tough export restrictions this month.

24 Mar 2016

Netflix Inc said it had been lowering the quality of its video for customers watching its service on wireless networks such as AT&T and Verizon Communications for more than five years, The Wall Street Journal reported on Thursday.

24 Mar 2016

View original post here:

Technology News | Reuters.com

Posted in Technology | Comments Off on Technology News | Reuters.com

Space Foundation Statement on President's Proposed NASA Budget

Posted: February 3, 2015 at 6:49 pm

Washington, D.C.,(Feb. 2, 2015) — The Space Foundation today said it supports President Obama’s FY2016 budget request for the National Aeronautics and Space Administration (NASA). That request, released today, calls for a FY2016 top line budget of $18.5 billion for the nation’s space agency — a $519 million increase over what Congress approved for the current fiscal year.

“The President’s request is a move in the right direction,” said Space Foundation Chief Executive Officer Elliot Pulham.

“The U.S. investment in NASA is a strategic investment in the future — one that fuels our technology base, our global economic competitiveness, and our ability to lead international partnerships,” Pulham said.”In that context, we believe the NASA budget can, and should, continue to grow.The President’s FY2016 budget request preserves International Space Station operations through 2024, increases NASA science programs by $43 million to $5.29 billion, keeps the SLS-Orion program on track to provide capabilities for human exploration beyond low earth orbit, and preserves a space technology budget of $724.8 million.

“The proposed budget also includes a credible aeronautics program, funded at $571.4 million,” Pulham said, “and, very importantly, it keeps commercial crew transport programs on track with $1.2 billion in funding toward a competitive, two-supplier system that will return America to human spaceflight operations in just two years’ time.”

About the Space Foundation Founded in 1983, the Space Foundation is the foremost advocate for all sectors of space, and is a global, nonprofit leader in space awareness activities, educational programs and major industry events, including the annualSpace Symposium, in support of its mission “to advance space-related endeavors to inspire, enable and propel humanity.” Space Foundation World Headquarters in Colorado Springs, Colo., USA, has a publicDiscovery Center, includingEl Pomar Space Gallery,Northrop Grumman Science Center featuring Science On a Sphere and the Lockheed Martin Space Education Center.The Space Foundation has a field office in Houston, and conducts government affairs from its Washington, D.C., office.It annually publishesThe Space Report: The Authoritative Guide to Global Space Activity,andthrough itsSpace CertificationandSpace Technology Hall of Fame programs,recognizes space-basedinnovations that have been adapted to improve life on Earth. Visitwww.SpaceFoundation.org, follow us onFacebook,Instagram,LinkedIn,Pinterest,TwitterandYouTube,and read our e-newsletterSpace Watch.

# # #

Please follow SpaceRef on Twitter and Like us on Facebook.

Continued here:
Space Foundation Statement on President's Proposed NASA Budget

Posted in Space Station | Comments Off on Space Foundation Statement on President's Proposed NASA Budget

23andMe Gives Pfizer DNA Data as Startup Seeks Growth

Posted: January 12, 2015 at 8:48 pm

Jan. 12 (Bloomberg) — 23andMe Director of Business Development Emily Drabant Conley discusses her companys collaboration with Pfizer to help find new targets to treat disease and to design clinical trials. She speaks on “Bloomberg West.” (Source: Bloomberg)

23andMe Inc., the genetic-testing startup backed by Google Inc. (GOOG), is sharing DNA data on about 650,000 individuals with Pfizer Inc. (PFE), to help find new targets to treat disease and to design clinical trials.

The collaboration with Pfizer is the broadest announced so far in 23andMes ambitious plan to become a repository for humanitys genetic makeup, and to turn data gathered from $99 saliva tests sold to consumers into multimillion-dollar deals with drugmakers.

The agreement unveiled today gives the U.S.s largest drugmaker access to anonymous, aggregated information from consumers who bought 23andMes test over the past seven years to learn about their own genetic histories. It includes only people who agreed to let their data be used in research. Pfizer and 23andMe declined to give the deals value.

Related: 23andme Aims to End FDA Standoff This Year After Public Shaming

The Silicon Valley startup, named for the 23 pairs of chromosomes in human cells, is betting its growing troves of genetic data will prove essential to drug companies, medical researchers and even health and wellness companies.

Even as it seeks to expand its consumer tests around the world, the company is repairing relations with the U.S. Food and Drug Administration. An agency ruling in late 2013 left 23andMe unable to sell health analyses from the saliva tests.

Anne Wojcicki, co-founder and chief executive officer of 23andMe Inc., speaks during a Bloomberg Television interview in San Francisco, California, on Oct. 9, 2014. Close

Anne Wojcicki, co-founder and chief executive officer of 23andMe Inc., speaks during a… Read More

Close

See more here:
23andMe Gives Pfizer DNA Data as Startup Seeks Growth

Posted in DNA | Comments Off on 23andMe Gives Pfizer DNA Data as Startup Seeks Growth

Personal Genome Diagnostics, Inc. And Human Longevity, Inc …

Posted: at 8:47 pm

BALTIMORE and LA JOLLA, Calif., Jan. 12, 2015 /PRNewswire/ –Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced that HLI will have access to PGDx’s cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete. HLI has also licensed the PGDx Enterprise Solution platform, which is a turnkey solution that enables laboratories to conduct their own advanced cancer genomic testing using next-generation sequencing.

PGDx co-founder and Chief Medical Officer Luis Diaz, MD, noted, “As pioneers in the field of cancer genomics, we are delighted to be collaborating with HLI, a visionary company co-founded by genomics legend J. Craig Venter.” PGDx co-founder and Chief Scientific Officer Victor Velculescu, MD, PhD, added, “HLI’s commitment to changing the way medicine is practiced by systematically harnessing genomics data to address aging-associated diseases aligns well with our goal of transforming the treatment of cancer by enabling researchers, physicians and patients to use genomics data to advance and personalize cancer therapy.”

PGDx applies its advanced genomic methods to identify and characterize the unique genomic alterations in tumors using tissue and liquid biopsies from cancer patients. The ES platform utilizes PGDx’s proprietary bioinformatics software pipeline that provides industry-leading sensitivity and specificity, while maximizing accuracy in detecting multiple types of tumor-specific mutations. PGDx’s targeted gene panels focus on well-characterized genes that have been selected for their high biologic importance in cancer and their relevance to drug targets and pathways.

HLI is building the world’s largest and most comprehensive database of human genomic and phenotype data. The company has signed agreements with academic medical centers and large biotechnology companies to sequence and analyze human genomes, including those of cancer patients, to determine more precise treatments and more details about the specific tumor and cancer in that patient. The PGDx suite of solutions will enable even greater precision and detail for HLI’s customers and their patients.

As part of the agreement, HLI will perform sequencing and analysis for select PGDx customers and for their own research activities.

“Having access to PGDx’s capabilities, targeted cancer panels and Enterprise Solution platform for advanced cancer genomic testing is another important component to our already comprehensive and accurate database of human biological data,” said J. Craig Venter, PhD, HLI’s Co-founder, Chairman, and Chief Executive Officer. “We are excited to be partnering with PGDx and the extensive cancer genomics expertise and technology innovations developed by the world-class research team at PGDx.”

About Personal Genome DiagnosticsPersonal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncologyresearchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors. PGDx’s proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. Co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics who have extensive experience in the practical application of advanced genomic technologies to research, drug development and clinical practice. PGDx’s CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit http://www.personalgenome.com.

About Human Longevity, Inc.HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visitwww.humanlongevity.com

Contacts

PGDx Corporate: Antony Newton Chief Commercial Officer 443-602-8833 anewton@personalgenome.com

More:
Personal Genome Diagnostics, Inc. And Human Longevity, Inc …

Posted in Human Longevity | Comments Off on Personal Genome Diagnostics, Inc. And Human Longevity, Inc …

Personal Genome Diagnostics, Inc. And Human Longevity, Inc. Sign Cancer Genomics Agreement

Posted: at 8:47 pm

BALTIMORE and LA JOLLA, Calif., Jan. 12, 2015 /PRNewswire/ –Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced that HLI will have access to PGDx’s cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete. HLI has also licensed the PGDx Enterprise Solution platform, which is a turnkey solution that enables laboratories to conduct their own advanced cancer genomic testing using next-generation sequencing.

PGDx co-founder and Chief Medical Officer Luis Diaz, MD, noted, “As pioneers in the field of cancer genomics, we are delighted to be collaborating with HLI, a visionary company co-founded by genomics legend J. Craig Venter.” PGDx co-founder and Chief Scientific Officer Victor Velculescu, MD, PhD, added, “HLI’s commitment to changing the way medicine is practiced by systematically harnessing genomics data to address aging-associated diseases aligns well with our goal of transforming the treatment of cancer by enabling researchers, physicians and patients to use genomics data to advance and personalize cancer therapy.”

PGDx applies its advanced genomic methods to identify and characterize the unique genomic alterations in tumors using tissue and liquid biopsies from cancer patients. The ES platform utilizes PGDx’s proprietary bioinformatics software pipeline that provides industry-leading sensitivity and specificity, while maximizing accuracy in detecting multiple types of tumor-specific mutations. PGDx’s targeted gene panels focus on well-characterized genes that have been selected for their high biologic importance in cancer and their relevance to drug targets and pathways.

HLI is building the world’s largest and most comprehensive database of human genomic and phenotype data. The company has signed agreements with academic medical centers and large biotechnology companies to sequence and analyze human genomes, including those of cancer patients, to determine more precise treatments and more details about the specific tumor and cancer in that patient. The PGDx suite of solutions will enable even greater precision and detail for HLI’s customers and their patients.

As part of the agreement, HLI will perform sequencing and analysis for select PGDx customers and for their own research activities.

“Having access to PGDx’s capabilities, targeted cancer panels and Enterprise Solution platform for advanced cancer genomic testing is another important component to our already comprehensive and accurate database of human biological data,” said J. Craig Venter, PhD, HLI’s Co-founder, Chairman, and Chief Executive Officer. “We are excited to be partnering with PGDx and the extensive cancer genomics expertise and technology innovations developed by the world-class research team at PGDx.”

About Personal Genome DiagnosticsPersonal Genome Diagnostics (PGDx) provides advanced cancer genome analyses to oncologyresearchers, drug developers, clinicians and patients. The company uses advanced genomic methods and its deep expertise in cancer biology to identify and characterize the unique genomic alterations in tumors. PGDx’s proprietary methods for genome sequencing and analysis are complemented by its extensive experience in cancer genomics and clinical oncology. Co-founders Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics who have extensive experience in the practical application of advanced genomic technologies to research, drug development and clinical practice. PGDx’s CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit http://www.personalgenome.com.

About Human Longevity, Inc.HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visitwww.humanlongevity.com

Contacts

PGDx Corporate: Antony Newton Chief Commercial Officer 443-602-8833 anewton@personalgenome.com

See the original post:
Personal Genome Diagnostics, Inc. And Human Longevity, Inc. Sign Cancer Genomics Agreement

Posted in Human Longevity | Comments Off on Personal Genome Diagnostics, Inc. And Human Longevity, Inc. Sign Cancer Genomics Agreement

'Close but no cigar': SpaceX reland fails

Posted: January 10, 2015 at 2:45 pm

An unmanned Space Exploration Technologies mission blasted off on Saturday carrying cargo for the International Space Station, but efforts to reland the rocket on a sea platform failed, the firm said.

“Rocket made it to drone spaceport ship, but landed hard. Close, but no cigar this time,” Elon Musk, founder and chief executive of SpaceX, as the company is called, said on Twitter.

Read MoreDisruptors 2015: SpaceX

“Bodes well for the future,” he added.

The Dragon cargo capsule itself was successfully launched into space and is expected to dock with the space station on Monday.

Seeking to cut the cost of space launches, SpaceX hoped to bring the rocket back to Earth, aiming to land it on a floating platform in the Atlantic Ocean some 200 miles (322 km) off Jacksonville, Fla., north of the Cape Canaveral Air Force Station launch site.

A ship stationed near the platform tried to capture the touchdown on video, but it was too dark and foggy, Musk said.

Engineers will look to work out what went wrong by studying data relayed during the descent, as well as pieces of the rocket itself, he added.

“Ship itself is fine. Some of the support equipment on the deck will need to be replaced,” said Musk, who prior to the launch had put the odds of a successful touchdown on the first attempt at just 50 percent.

The primary purpose of Saturday’s mission was to deliver cargo to the space station, a $100-billion laboratory that flies about 260 miles (418 km) above Earth.

See more here:
'Close but no cigar': SpaceX reland fails

Posted in Space Station | Comments Off on 'Close but no cigar': SpaceX reland fails

NATO Secretary General with President of Afghanistan and Chief Executive, 01 DEC 2014 – Video

Posted: December 4, 2014 at 8:52 pm



NATO Secretary General with President of Afghanistan and Chief Executive, 01 DEC 2014
Joint press point with NATO Secretary General Jens Stoltenberg, President of the Islamic Republic of Afghanistan Mohammad Ashraf Ghani and the Chief Executive Abdullah Abdullah. Held at NATO…

By: NATO

See the original post here:
NATO Secretary General with President of Afghanistan and Chief Executive, 01 DEC 2014 – Video

Posted in NATO | Comments Off on NATO Secretary General with President of Afghanistan and Chief Executive, 01 DEC 2014 – Video

Bitcoin: Sink or swim?

Posted: at 8:49 pm

Updated: 2014-12-04 07:05 By Deng Yanzi in Hong Kong(HK Edition)

Editor’s note: We continue with our innovation series this week on exciting pioneering firms in the Pearl River Delta region, with the launch of BitMEX, a derivatives trading platform dedicated to users of the virtual currency, bitcoin.

Bitcoin has been on a rollercoaster ride since 2013. While the extreme volatility of the digital currency may make many flinch, some bitcoin holders seek ways to hedge the risk,while speculators seek an opportunity to profit from the seesawing value.

A newly launched derivatives exchange platform, Bitcoin Mercantile Exchange (BitMEX), aims to meet both those needs.

Arthur Hayes, co-founder and chief executive officer of BitMEX, says he modeled the platform on existing derivatives exchanges for fiat currency.

Traders can deposit bitcoin from their wallet into their BitMEX account, and use them as margin to buy and sell futures contracts, with 0.005 percent trading fee on a completed transaction.

BitMEX won the Hong Kong leg of the Slush startup pitching competition in October, advancing to the main Slush event in Helsinki, Finland, last month. However, it failed to win a place in the Nov 18-19 worldwide contest.

According to Hayes, the present fee pool for bitcoin derivatives is $120 million a year. He expects the market to grow to half a billion US dollars in the next five to seven years, and even bigger when bitcoin becomes globally recognized and gains higher worth.

The value of bitcoin has been extremely volatile, starting at less than 0.1 US cent and skyrocketing in 2013, peaking at approximately $1,240 that November before falling precipitously. The current value of bitcoin hovers around $360, a plunge of more than 60 percent since the start of the year.

See the rest here:
Bitcoin: Sink or swim?

Posted in Bitcoin | Comments Off on Bitcoin: Sink or swim?

Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company

Posted: at 8:46 pm

Duke University has signed an exclusive licensing agreement with Editas Medicine, a leading genome editing company, for genetic engineering technologies developed in the lab of Charles Gersbach, assistant professor of biomedical engineering. The agreement focuses on Gersbachs work with genome engineering technologies known as CRISPR/Cas9 and TALENs.

Charles Gersbach

The agreement allows broad use of the technology developed in Gersbachs lab for the prevention or treatment of human disease. To this point, Gersbachs most notable work in that field is on Duchenne muscular dystrophy, a genetic disease affecting one in 3,500 newborn males that currently has no approved treatment and causes muscular deterioration, paralysis and eventual death, usually by age 25. Gersbachs work is focused on using gene editing to correct the mutated gene that causes the disease, in contrast to treating the resulting symptoms of the disease. Gersbach has also pioneered the use of both CRISPR/Cas9 and TALEs for turning on genes in a way that could be used to treat degenerative disorders or compensate for genetic defects.

Charlies deep expertise in both genome editing and in this area of biology is a tremendous asset as we begin to understand how to apply genome editing technologies to specific diseases, said Katrine Bosley, chief executive officer of Editas Medicine. Gersbach is also serving as a scientific advisor to Editas.

Editas is a leading genome editing company and part of a transformational new area of healthcaregenomic medicine. The company was founded by the pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The companys mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases.

View original post here:
Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company

Posted in Genetic Engineering | Comments Off on Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company

NATO, Afghan leaders say they are ready to move to new phase

Posted: December 1, 2014 at 11:48 pm

Published December 01, 2014

BRUSSELS Leaders of Afghanistan and NATO say they are ready to move to a new phase in their relations the end of NATO-led combat operations in the violence-torn country effective Jan. 1.

Afghan President Ashraf Ghani and Chief Executive Abdullah Abdullah arrived at NATO headquarters on Monday for talks with alliance Secretary-General Jens Stoltenberg.

Abdullah said that following the signature by Ghani on Sunday of a status of forces agreement with NATO, the “legal framework is now fully in place” for the U.S. and other alliance member nations to shift in 2015 to a mission of training, advising and assisting Afghanistan’s security forces.

Foreign ministers of the 28 NATO member countries are scheduled to meet Tuesday in Brussels. They are expected to approve the new Afghan mission, named Resolute Support.

See original here:
NATO, Afghan leaders say they are ready to move to new phase

Posted in NATO | Comments Off on NATO, Afghan leaders say they are ready to move to new phase